Reports

Sale

Non-Small Cell Lung Cancer Treatment Market

Global Non-Small Cell Lung Cancer Treatment Market: Epidemiology, Market Landscape, Size, Share, By Type: Adenocarcinoma, Large Cell Carcinoma, Others; By Treatment Type; By Drug Class; By Therapy Type; By Distribution Channel; By End User; Regional Analysis; Patent Analysis; Clinical Trials Analysis; Supplier Landscape; 2024-2032

Global Non-Small Cell Lung Cancer Market Outlook

The global non-small cell lung cancer treatment market size attained a value of about USD 19.38 billion in 2023. The market is likely to grow at a rate of 10% during the forecast period of 2024-2032 to reach a value of nearly USD 45.70 billion by 2032. The growth of the market can be attributed to the growing demand for diagnostics and therapeutics..

 

non-small cell lung cancer treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Non-Small Cell Lung Cancer Market: Introduction

Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer. There is an abnormal growth of cancerous cells in the lung tissues. This cancer is coined as “non-small” due to the presence of larger abnormal cells, in comparison to small cell lung cancer. The three types of non-small cell lung cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

 

The signs and symptoms of non-small cell lung cancer consist of cough, shortness of breath, chest pain, hoarseness, wheezing, loss of appetite, and difficulty in swallowing and breathing.

 

The exact cause of non-small cell lung cancer is unknown, but the disease is set to be triggered by several risk factors, including smoking, air pollution, and exposure to certain metals, mineral dust, asbestos, radon, and harmful radiations. This type of cancer can also occur because of associated disorders, such as chronic obstructive pulmonary disorder, pulmonary fibrosis, and HIV or AIDS.

 

The diagnosis of non-small cell lung cancer is done with the help of laboratory tests and chest X-rays. CT scans, biopsy, and sputum cytology are the confirmatory diagnostic measures used to analyse the anatomy of the lungs and other respiratory organs. Bronchoscopy and thoracoscopy are the procedures used to examine the airways and chest.

 

The non-small cell lung cancer consists of several stages, depending on the spreading of the cancerous cells. The treatment strategies are incorporated based on the different stages- stage 0, stage I, stage II, stage III, and stage IV. NSCLC accounts for nearly 85 per cent of all lung cancers prevalent across the world.

 

Non-Small Cell Lung Cancer Market Segmentations

The non-small cell lung cancer treatment market can be categorised into the following segments:

 

non-small cell lung cancer treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Type

  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Others

 

Market Breakup by Treatment Type

  • Immunotherapy
  • Chemotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Others

 

Market Breakup by Drug Class

  • Alkylating Agents
  • Epidermal Growth Factor Receptor Blocker
  • Antimetabolites
  • Mitotic Inhibitors
  • Multi-kinase Inhibitors
  • Others

 

Market Breakup by Therapy Type

  • Single Drug Therapy
  • Combination Therapy

 

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

 

Market Breakup by End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

non-small cell lung cancer treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Non-Small Cell Lung Cancer Treatment Market Scenario

Increasing prevalence of non-small cell lung cancer has been driving the market growth. NSCLC accounts for 80-85 per cent of all the prevalent lung cancer cases globally. This can be attributed to the increased demand for the non-small cell lung cancer treatment market.

 

The growing demand for diagnostics and therapeutics has stimulated the focus of big pharmaceutical companies towards constant research and innovation for advanced treatment care, bolstering the efficacy of the existing therapeutics. The rising investments by the key players in the research and development activities and favouring government initiatives are anticipated to fuel the market growth further.

 

The market growth can further be accelerated by the increasing number of diagnoses and improving healthcare-related awareness. The entry of advanced and novel therapeutic interventions is also expected to aid the expansion of the non-small cell lung cancer treatment market. The introduction of targeted therapies and sophisticated treatment facilities has led to significant advancements in healthcare.

 

North America is anticipated to dominate the regional markets owing to the increase in the patient pool, a growing number of chain smokers, and the existence of advanced immunotherapies. Europe is also expected to hold a significant share in the non-small cell lung cancer treatment market because of the rising adoption of advanced therapeutics and improved awareness.

 

Non-Small Cell Lung Cancer Treatment Market Therapeutic Landscape

The treatment of non-small cell lung cancer treatment is dependent on the extent of distribution of cancerous cells. There are different treatment regimens based on the stage of cancer and the affected areas of the body. Surgery is the first-line treatment for most of the diagnosed cases. In these procedures, the tumour is removed, including the surrounding healthy tissue around that tumour.

 

Radiofrequency ablation and radiation therapy are also used for surgery-intolerant patients. In radiofrequency ablation, the surgeon eradicates the cancerous cells by heating the tumour with high-energy radio waves. Radiation therapy is based on the killing of cancerous cells with the help of powerful X-ray beams.

 

Chemotherapy is the most commonly used procedure for the management of non-small cell lung cancer. This therapy adheres to the further growth of the cancerous cells and hence, stops the further spread of cancer. Chemotherapy can be given through oral and intravenous routes.

 

With extensive research, targeted drug therapies have been discovered and have improved therapeutic effects. The targeted drug therapies act by specific targeting abnormal cells without hampering the healthy cells. The two commonly used targeted therapies are tyrosine inhibitors and monoclonal antibodies.

 

Immunotherapy is another therapeutic procedure based on the application of certain drugs to boost the strength of the immunity system. This assists the immune system to identify its healthy cells and cancerous cells. The drugs used in immunotherapy are called checkpoint inhibitors and include atezolizumab, pembrolizumab, and cemiplimab. The increased demand for these targeted immunotherapies has attributed to the growth of the non-small cell lung cancer treatment market growth during the forecast period.

 

Non-Small Cell Lung Cancer Treatment Market- Clinical Trials Landscape- Novel Therapeutic Products Under Pipeline

The recent discovery of novel targeted therapies has been of major interest to experts, researchers, and key players. Tremendous efforts and intensive research and development are under process for immunotherapy and tyrosine kinase inhibitors. Despite the discovery of many novel oncological agents, the focus of the scientists is to explore the optimisation of new therapeutic interventions into clinical practice.

 

AstraZeneca, a key market trial, has funded the clinical trials of the novel drug, Osimertinib. The ongoing ADAURA trials for this drug have shown some promising effects for the treatment of early-stage EGFRm non-small cell lung cancer. The drug has also reduced the chances of disease recurrence in patients during clinical studies.

 

Sapanisertib, an investigational drug, discovered by Calithera Biosciences has been granted fast-track approval by the FDA for the treatment of non-small cell lung cancer. This drug is specifically approved for the treatment of the mutated nuclear erythroid 2-related factor tumours and is still under further investigation. This type of mutation is prevalent in around 15 per cent of the patients suffering from metastatic squamous non-small cell lung cancer.

 

GlaxoSmithKline, a major company, is performing Phase III clinical trials for the Jemperli drug. This drug has shown positive effects in the phase II trials, and henceforth, progressed to the advanced stages for further assessment.

 

Recently, FDA has given fast-track approval to the combination therapy of Pembrolizumab and Eftilagimod Alpha for the treatment of the first line of non-small cell lung cancer. This will stimulate the therapeutic prospects in the field of immunotherapy and will provide more effective and durable solutions to the patients.

 

The significant advancements have led to the discovery of many novel therapeutic products, once approved, these drugs are anticipated to bolster the non-small cell lung cancer treatment market growth and development.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the non-small cell lung cancer treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

 

  • Genentech, Inc. (F. Hoffmann-La Roche Ltd)
  • Eli Lilly and Company
  • Celgene Corporation (Bristol-Myers Squibb Company)
  • Pfizer Inc.
  • AstraZeneca
  • Sanofi
  • Novartis AG
  • Astellas Pharma Inc.
  • Boehringer Ingelheim International GmbH
  • Merck & Co. Inc.
  • Takeda Pharmaceutical Company Limited
  • Clovis Oncology
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Treatment Type
  • Drug Class
  • Therapy Type
  • Distribution Channel
  • End User
  • Region
Breakup by Type
  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Others
Breakup by Treatment Type
  • Immunotherapy
  • Chemotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Others
Breakup by Drug Class
  • Alkylating Agents
  • Epidermal Growth Factor Receptor Blocker
  • Antimetabolites
  • Mitotic Inhibitors
  • Multi-kinase Inhibitors
  • Others
Breakup by Therapy Type
  • Single Drug Therapy
  • Combination Therapy
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others
Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Genentech, Inc. (F. Hoffmann-La Roche Ltd)
  • Eli Lilly and Company
  • Celgene Corporation (Bristol-Myers Squibb Company)
  • Pfizer Inc.
  • AstraZeneca
  • Sanofi
  • Novartis AG
  • Astellas Pharma Inc.
  • Boehringer Ingelheim International GmbH
  • Merck & Co. Inc.
  • Takeda Pharmaceutical Company Limited
  • Clovis Oncology
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Non-Small Cell Lung Cancer Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Non-Small Cell Lung Cancer Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Non-Small Cell Lung Cancer Epidemiology (2016-2031)
    5.3    Europe Non-Small Cell Lung Cancer Epidemiology (2016-2031)
    5.4    Asia-Pacific Non-Small Cell Lung Cancer Epidemiology (2016-2031)
    5.5    Latin America Non-Small Cell Lung Cancer Epidemiology (2016-2031)
    5.6    Middle East & Africa Non-Small Cell Lung Cancer Epidemiology (2016-2031)
6    Global Non-Small Cell Lung Cancer Treatment Market Overview
    6.1    Global Non-Small Cell Lung Cancer Treatment Market Historical Value (2017-2023) 
    6.2    Global Non-Small Cell Lung Cancer Treatment Market Forecast Value (2024-2032)
7    Global Non-Small Cell Lung Cancer Treatment Market Landscape
    7.1    Non-Small Cell Lung Cancer: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Non-Small Cell Lung Cancer: Product Landscape
        7.2.1    Analysis by Type
        7.2.2    Analysis by Treatment Type
        7.2.3    Analysis by Drug Class
        7.2.4    Analysis by Therapy Type
        7.2.5    Analysis by Distribution Channel
        7.2.6    Analysis by End User
8    Non-Small Cell Lung Cancer : Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Non-Small Cell Lung Cancer Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Non-Small Cell Lung Cancer Treatment Market Segmentation
    11.1    Global Non-Small Cell Lung Cancer Treatment Market by Type 
        11.1.1    Market Overview
        11.1.2    Adenocarcinoma
        11.1.3    Squamous Cell Carcinoma
        11.1.4    Large Cell Carcinoma  
        11.1.5    Others
    11.2    Global Non-Small Cell Lung Cancer Treatment Market by Treatment Type
        11.2.1    Market Overview
        11.2.2    Immunotherapy
        11.2.3    Chemotherapy
        11.2.4    Radiation Therapy
        11.2.5    Targeted Therapy
        11.2.6    Others
    11.3    Global Non-Small Cell Lung Cancer Treatment Market by Drug Class
        11.3.1    Market Overview
        11.3.2    Alkylating Agents
        11.3.3    Epidermal Growth Factor Receptor Blocker
        11.3.4    Antimetabolites
        11.3.5    Mitotic Inhibitors
        11.3.6    Multi-kinase Inhibitors
        11.3.7    Others  
    11.4    Global Non-Small Cell Lung Cancer Treatment Market by Therapy Type
        11.4.1    Market Overview
        11.4.2    Single Drug Therapy
        11.4.3    Combination Therapy
    11.5    Global Non-Small Cell Lung Cancer Treatment Market by Distribution Channel
        11.5.1    Market Overview
        11.5.2    Hospital Pharmacies
        11.5.3    Retail Pharmacies
        11.5.4    Online
        11.5.5    Others
    11.6    Global Non-Small Cell Lung Cancer Treatment Market by End User
        11.6.1    Market Overview
        11.6.2    Hospitals
        11.6.3    Homecare
        11.6.4    Specialty Clinics
        11.6.5    Others
    11.7    Global Non-Small Cell Lung Cancer Treatment Market by Region
        11.7.1    Market Overview
        11.7.2    North America
        11.7.3    Europe 
        11.7.4    Asia Pacific
        11.7.5    Latin America
        11.7.6    Middle East and Africa
12    North America Non-Small Cell Lung Cancer Treatment Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Non-Small Cell Lung Cancer Treatment Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Non-Small Cell Lung Cancer Treatment Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Non-Small Cell Lung Cancer Treatment Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Non-Small Cell Lung Cancer Treatment Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Genentech, Inc. (F. Hoffmann-La Roche Ltd)
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Eli Lilly and Company
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Celgene Corporation (Bristol-Myers Squibb Company)
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Pfizer Inc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    AstraZeneca
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Sanofi
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Novartis AG
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Astellas Pharma Inc.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Boehringer Ingelheim International GmbH 
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Merck & Co. Inc.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Takeda Pharmaceutical Company Limited
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Clovis Oncology
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
    23.13    Johnson & Johnson Services, Inc.
        23.13.1    Financial Analysis
        23.13.2    Product Portfolio
        23.13.3    Demographic Reach and Achievements
        23.13.4    Mergers and Acquisitions
        23.13.5    Certifications
    23.14    Teva Pharmaceutical Industries Ltd.
        23.14.1    Financial Analysis
        23.14.2    Product Portfolio
        23.14.3    Demographic Reach and Achievements
        23.14.4    Mergers and Acquisitions
        23.14.5    Certifications
24    Non-Small Cell Lung Cancer Treatment - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 19.38 billion in 2023, driven growing demand for diagnostics and therapeutics.

The market is likely to grow at a rate of 10% during the forecast period of 2024-2032 to reach a value of nearly USD 45.70 billion by 2032.

The market growth is primarily driven by the rising cases of lung cancer, the growing number of chain smokers, the rising adoption of advanced healthcare, and increasing research and developmental activities.

The major types of non-small cell lung cancer include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, among others.

The treatment types used in the market include immunotherapy, chemotherapy, radiation therapy, and targeted therapy, among others.

The drug classes used in treatment include alkylating agents, epidermal growth factor receptor blocker, antimetabolites, mitotic inhibitors, and multi-kinase inhibitors, among others.

The therapy types can be divided into single drug therapy and combination therapy.

The distribution channels used in the treatment market include hospital pharmacies, retail pharmacies, and online channels, among others.

The end-user segments can be divided into hospitals, homecare, and specialty clinics, among others.

The different regions in the market are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America is anticipated to hold the largest share of the during the forecast period.

The key companies involved in the market are Genentech, Inc. (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation (Bristol-Myers Squibb Company), Pfizer Inc., AstraZeneca, Sanofi, Novartis AG, Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Clovis Oncology, Johnson & Johnson Services, Inc., and Teva Pharmaceutical Industries Ltd., among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER